


World Biotech 2005

Graph 4.3: Total Global Biopharmaceutical Revenue (\$bn), 2003-2004



source: visiongain, 2005

4.4 The Top 20 Selling Biopharm Drugs of 2004 Accounted For 62% of Total Revenues

The top 20 selling biopharmaceuticals in 2004 generated a total of \$35.1bn, accounting for 62.4% of total sales of all biopharmaceuticals in that year. Compared to a change in revenues from 2003, total sales of the 20 products grew 537.9% (Table 4.8, Chart 4.3). As mentioned above the top selling product was Johnson & Johnson's Procrit/Eprex for anaemia with sales of \$3589m. Eli Lilly's insulin product Humulin made 20th place with sales of \$998, just falling short of all biopharmaceuticals that made the top 20 in 2004 were of blockbuster status (Table 4.8, Graph 4.4). Of the top 20 biopharmaceuticals, 3 were monoclonal antibodies (Remicade, Enbrel and Gleevec) and 11 were recombinant products (Table 4.8). The treatment of blood disorders had the highest number of drugs within the top 20 products of 2004 with 4 products (Procrit/Eprex, Epogen, Aransep and NeoRecomon/Epogin). These products generated \$10.5bn in 2004, with blood disorders featuring as the highest earning disease of the top 20 selling biopharmaceuticals (Table 4.8)